As news outlets reported last week, the Office of Management and Budget has completed its review of HHS’s proposed rule regarding the 340B discount drug program, which is expected to address the application of Civil Monetary Penalties for drug manufacturers who charge providers unauthorized prices for drugs.  The proposed rule is expected to be released soon.